Black Patients With Overactive Bladder Less Likely to Receive β3-Adrenoceptor…
Lori Solomon
FRIDAY, May 26, 2023 (HealthDay News) -- Black individuals are significantly less likely than non-Hispanic White individuals to…
Browsing Tag
Bladder
Immunotherapy Combo Shows Promise in Tough-to-Treat, Early Bladder Cancer
Preliminary findings presented at the American Urological Association (AUA) annual meeting…
Medical ‘microrobots’ could one day treat bladder disease, other human…
A team of engineers at the University of Colorado Boulder has designed a new class of tiny, self-propelled robots that can zip through liquid at incredible speeds -- and may one day even…
Anti-PD-1 in BCG-Unresponsive Papillary Bladder Tumors
Pembrolizumab (Keytruda) demonstrated antitumor activity in patients with bacillus…
How Do Symptoms of Cystitis, Overactive Bladder Differ?
Elana Gotkine
MONDAY, May 8, 2023 (HealthDay News) -- The characteristics of pain, pressure, discomfort, and urgency vary for patients with interstitial…
Novel Chemo Delivery System Achieves High Response Rate in Bladder Cancer
CHICAGO -- An investigational intravesical delivery system designed to provide sustained local release of gemcitabine into the…
‘Fantastic,’ ‘Terrific’ Results With Oncolytic Virus Combo…
CHICAGO -- An oncolytic virus therapy combined with pembrolizumab (Keytruda) produced complete responses (CRs) in 85% of…
Overactive Bladder Treatment Market Is Expected to Generate $3.5 Billion by 2031:…
<!-- Name:DistributionId Value:8801919 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
FDA Greenlights New First-Line Regimen in Bladder Cancer
The FDA gave accelerated approval to enfortumab vedotin (Padcev) and pembrolizumab…
Overactive Bladder Treatment Market to Hit USD 4.89 Billion by 2030 driven by the…
<!-- Name:DistributionId Value:8801971 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…